FindTrial
Sign In

Prognostic parameter in patients having therapy-related myeloid neoplasms after peptide receptor radionuclide therapy (PRRT) and peptide receptor radioligand therapy (PRLT) over 20 years’ experience

Prognostic parameter in patients having therapy-related myeloid neoplasms after peptide receptor radionuclide therapy (PRRT) and peptide receptor radioligand therapy (PRLT) over 20 years’ experience

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20200428005
Enrollment
386
Registered
2020-04-28
Start date
2004-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

therapy&#45

Interventions

patients who had therapy&#45
related myeloid neoplasm after PRRT&#44
and PRLT
Other
t&#45
MN patients

Sponsors

None
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients who had therapy-related myeloid neoplasm after receiving peptide receptor radionuclide therapy and peptide receptor radioligand therapy

Exclusion criteria

Exclusion criteria: Patient under 18 years old

Design outcomes

Primary

MeasureTime frame
overall survival (death, alive status) at the end of the study death or alive status from data record—

Secondary

MeasureTime frame
N/A N/A N/A—

Countries

Thailand

Contacts

Public ContactMaythinee Chantadisai

Chulalongkorn University, King Chulalongkorn Memorial Hospital

aueng_tw45@hotmail.com+66840726110

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026